Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.…
PRPO Stock Slips Post Q3 Earnings Despite Revenue and Product Growth
Precipio (NASDAQ: PRPO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 61 employees.
The shares were at 17.35 USD on 20 November 2026, down 14.5% over 52 weeks. Its 52-week range is 17.30 USD to 33.63 USD, and it trades at the bottom of that range.
Its market capitalisation is 31.11M USD.
Precipio reports return on equity of -2.5%, an operating margin of -5.3% and revenue up 8.3% year over year.
Its debt exceeds its cash by 116.00K USD, a debt-to-equity ratio of 0.25. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.